Stromal control of chronic lymphocytic leukemia cells

被引:1
作者
Etet, Paul Faustin Seke
Kamdje, Armel Herve Nwabo
Amvene, Jeremie Mbo
Aldebasi, Yousef
Farahna, Mohammed
Vecchio, Lorella
机构
关键词
chronic lymphoblastic leukemia; CLL; signaling pathways; cancer; stromal cells;
D O I
10.2147/RRB.S35388
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
ongoing efforts to develop therapies against chronic lymphocytic leukemia (CLL), stromal factors allowing malignant cells to escape spontaneous and chemotherapymediated apoptosis, giving way to relapses, have been abundantly investigated. Bone marrow adherent cell types, collectively referred to as stromal cells, appear to be key players in such escape, mainly because CLL malignant cells, which rapidly undergo spontaneous apoptosis when cultured in vitro, survive, migrate, and resist cytotoxic agents in co-culture with bone marrow stromal cells. CLL displays variable clinical courses according to well-defined prognostic factors induced on malignant B-cells (CLL cells) or expressed by the transformed bone marrow stromal microenvironment. Particularly, a critical pathogenic role is played by proinflammatory factors, adhesion molecules, and signaling molecules involved in cell fate and stemness, such as Notch, Wnt, sonic Hedgehog, phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and the B-cell CLL/lymphoma 2 (Bcl-2) family of regulator proteins. As herein discussed, these molecules probably form a complex network favoring CLL cell survival, proliferation, and chemoresistance to anticancer therapy. Characterizing the sets of signaling pathways involved in the interactions between stromal cells and CLL cells may provide new tools for CLL clinical phenotyping and for re-sensitizing chemotherapy resistant cells.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 118 条
[1]   Notch signaling: Cell fate control and signal integration in development [J].
Artavanis-Tsakonas, S ;
Rand, MD ;
Lake, RJ .
SCIENCE, 1999, 284 (5415) :770-776
[2]  
Aziz KA, 2000, BLOOD, V96, P3161
[3]   Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [J].
Badoux, Xavier C. ;
Keating, Michael J. ;
Wen, Sijin ;
Wierda, William G. ;
O'Brien, Susan M. ;
Faderl, Stefan ;
Sargent, Rachel ;
Burger, Jan A. ;
Ferrajoli, Alessandra .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :584-591
[4]   AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance [J].
Balakrishnan, Kumudha ;
Burger, Jan A. ;
Wierda, William G. ;
Gandhi, Varsha .
BLOOD, 2009, 113 (01) :149-153
[5]   NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion [J].
Baldoni, Stefano ;
Sportoletti, Paolo ;
Del Papa, Beatrice ;
Aureli, Patrizia ;
Dorillo, Erica ;
Rosati, Emanuela ;
Ciurnelli, Raffaella ;
Marconi, Pierfrancesco ;
Falzetti, Franca ;
Di Ianni, Mauro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (02) :153-157
[6]   Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737 [J].
Bates, Darcy J. P. ;
Danilov, Alexey V. ;
Lowrey, Christopher H. ;
Eastman, Alan .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) :1504-1514
[7]   Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation [J].
Bhardwaj, G ;
Murdoch, B ;
Wu, D ;
Baker, DP ;
Williams, KP ;
Chadwick, K ;
Ling, LE ;
Karanu, FN ;
Bhatia, M .
NATURE IMMUNOLOGY, 2001, 2 (02) :172-180
[8]   Stereotypical Chronic Lymphocytic Leukemia B-Cell Receptors Recognize Survival Promoting Antigens on Stromal Cells [J].
Binder, Mascha ;
Lechenne, Barbara ;
Ummanni, Ramesh ;
Scharf, Christan ;
Balabanov, Stefan ;
Trusch, Maria ;
Schlueter, Hartmut ;
Braren, Ingke ;
Spillner, Edzard ;
Trepel, Martin .
PLOS ONE, 2010, 5 (12)
[9]   A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) [J].
Bleul, CC ;
Fuhlbrigge, RC ;
Casasnovas, JM ;
Aiuti, A ;
Springer, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1101-1109
[10]   Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials [J].
Brown, Jennifer R. .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) :1-6